KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Operating Expenses (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Other Operating Expenses for 13 consecutive years, with $3.0 million as the latest value for Q1 2026.

  • For Q1 2026, Other Operating Expenses rose 103.9% year-over-year to $3.0 million; the TTM value through Mar 2026 reached $17.4 million, up 65.56%, while the annual FY2025 figure was $15.9 million, 132675.0% up from the prior year.
  • Other Operating Expenses hit $3.0 million in Q1 2026 for Ionis Pharmaceuticals, down from $8.0 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $756.8 million in Q4 2022 and bottomed at $1.1 million in Q3 2024.
  • Average Other Operating Expenses over 5 years is $47.4 million, with a median of $3.0 million recorded in 2026.
  • Year-over-year, Other Operating Expenses plummeted 99.6% in 2023 and then soared 118.3% in 2025.
  • Ionis Pharmaceuticals' Other Operating Expenses stood at $756.8 million in 2022, then tumbled by 99.6% to $3.1 million in 2023, then increased by 25.09% to $3.8 million in 2024, then skyrocketed by 107.81% to $8.0 million in 2025, then tumbled by 62.51% to $3.0 million in 2026.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $3.0 million, $8.0 million, and $2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.